NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free EMBC Stock Alerts $10.40 -0.49 (-4.50%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$10.33▼$10.7750-Day Range$10.24▼$14.9552-Week Range$9.93▼$32.00Volume488,927 shsAverage Volume412,285 shsMarket Capitalization$598.83 millionP/E Ratio10.95Dividend Yield5.77%Price Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Embecta alerts: Email Address Embecta MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside53.8% Upside$16.00 Price TargetShort InterestHealthy4.60% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingAcquiring Shares$32,500 Bought Last QuarterProj. Earnings Growth3.27%From $2.14 to $2.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector321st out of 907 stocksSurgical & Medical Instruments Industry38th out of 96 stocks 2.8 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.60% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Embecta has recently decreased by 17.26%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 5.51%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 27.15% next year. This indicates that Embecta will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 1.8 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Embecta this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to grow by 3.27% in the coming year, from $2.14 to $2.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 10.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 10.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.60. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Embecta Stock (NASDAQ:EMBC)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesApril 23, 2024 | globenewswire.comembecta to Report Fiscal Second Quarter 2024 Financial ResultsApril 21, 2024 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Shares Up 3.5%April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Hits New 12-Month Low at $10.09April 16, 2024 | finance.yahoo.comEmbecta Corp. (EMBC) Stock Historical Prices & Data - Yahoo FinanceMarch 11, 2024 | finance.yahoo.comEMBC Apr 2024 10.000 putMarch 11, 2024 | finance.yahoo.comEMBC Apr 2024 20.000 callMarch 6, 2024 | globenewswire.comembecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 DiabetesApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 13, 2024 | finance.yahoo.comEmbecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15February 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)February 10, 2024 | markets.businessinsider.comEmbecta Shareholders Approve Directors and Compensation PlansFebruary 10, 2024 | insidermonkey.comEmbecta Corp. (NASDAQ:EMBC) Q1 2024 Earnings Call TranscriptFebruary 9, 2024 | marketwatch.comEmbecta Shares Fall Despite Outlook Raise, Strong 1QFebruary 9, 2024 | markets.businessinsider.comEmbecta Sinks As Outlook Comes In Below ConsensusFebruary 9, 2024 | finance.yahoo.comWhy Embecta Stock Is Tanking TodayFebruary 9, 2024 | fool.comWhy Embecta Stock Is Tanking TodayFebruary 9, 2024 | msn.comEmbecta beats top-line and bottom-line estimates; updates FY24 outlookFebruary 9, 2024 | finance.yahoo.comEmbecta Corp. Reports First Quarter Fiscal 2024 Financial ResultsFebruary 9, 2024 | finance.yahoo.comEmbecta Corp (EMBC) Reports Modest Revenue Growth and Decline in Profitability in Q1 Fiscal 2024February 8, 2024 | benzinga.comEarnings Preview For EmbectaFebruary 7, 2024 | finance.yahoo.comembecta to Participate in the 11th Annual BTIG MedTech ConferenceJanuary 24, 2024 | finance.yahoo.comembecta to Report Fiscal First Quarter 2024 Financial ResultsJanuary 9, 2024 | finanznachrichten.deEmbecta Corp.: embecta Announces FDA 510(k) Submission for Insulin Patch PumpJanuary 9, 2024 | finance.yahoo.comembecta Announces FDA 510(k) Submission for Insulin Patch PumpDecember 14, 2023 | finance.yahoo.comembecta to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 1, 2023 | finance.yahoo.comEmbecta Corp's Dividend AnalysisSee More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/09/2024Ex-Dividend for 3/15 Dividend2/27/2024Dividend Payable3/15/2024Today4/25/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+53.8%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio10.95 Forward P/E Ratio4.86 P/E GrowthN/ANet Income$70.40 million Net Margins4.93% Pretax Margin5.69% Return on Equity-18.66% Return on Assets12.38% Debt Debt-to-Equity RatioN/A Current Ratio2.20 Quick Ratio1.75 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.53 Cash Flow$3.53 per share Price / Cash Flow2.95 Book Value($14.34) per share Price / Book-0.73Miscellaneous Outstanding Shares57,580,000Free Float57,418,000Market Cap$598.83 million OptionableOptionable Beta0.73 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 56)President, CEO & Director Comp: $2.2MMr. Jacob P. Elguicze (Age 51)Senior VP & CFO Comp: $1.05MMr. Brian R. Capone (Age 49)VP, Chief Accounting Officer & Corporate Controller Comp: $645.16kMr. Jeffrey Z. Mann (Age 52)Senior VP, General Counsel, Head of Business Development & Corporate Secretary Comp: $959.45kMr. Shaun Curtis (Age 55)Senior Vice President of Global Manufacturing & Supply Chain Comp: $915.67kMs. Colleen Riley (Age 60)Senior VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSenior Vice President of Global Marketing & Product ManagementMs. Jean M. Casner (Age 66)Senior VP & Chief Human Resources Officer Mr. Tom Blount (Age 50)Senior VP & President of North America More ExecutivesKey CompetitorsSI-BONENASDAQ:SIBNTreace Medical ConceptsNASDAQ:TMCISilk Road MedicalNASDAQ:SILKAtrionNASDAQ:ATRIIradimedNASDAQ:IRMDView All CompetitorsInsiders & InstitutionsDenali Advisors LLCSold 11,349 shares on 4/19/2024Ownership: 0.088%Allspring Global Investments Holdings LLCSold 12,893 shares on 4/18/2024Ownership: 0.043%Cardinal Capital ManagementBought 10,062 shares on 4/16/2024Ownership: 0.017%PNC Financial Services Group Inc.Sold 5,805 shares on 3/22/2024Ownership: 0.051%Vanguard Group Inc.Bought 20,509 shares on 3/11/2024Ownership: 12.202%View All Insider TransactionsView All Institutional Transactions EMBC Stock Analysis - Frequently Asked Questions Should I buy or sell Embecta stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" EMBC shares. View EMBC analyst ratings or view top-rated stocks. What is Embecta's stock price target for 2024? 2 brokers have issued 12 month target prices for Embecta's stock. Their EMBC share price targets range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 53.8% from the stock's current price. View analysts price targets for EMBC or view top-rated stocks among Wall Street analysts. How have EMBC shares performed in 2024? Embecta's stock was trading at $18.93 at the beginning of the year. Since then, EMBC stock has decreased by 45.1% and is now trading at $10.40. View the best growth stocks for 2024 here. Are investors shorting Embecta? Embecta saw a decline in short interest in April. As of April 15th, there was short interest totaling 2,540,000 shares, a decline of 17.3% from the March 31st total of 3,070,000 shares. Based on an average trading volume of 427,700 shares, the days-to-cover ratio is presently 5.9 days. Approximately 4.6% of the shares of the company are short sold. View Embecta's Short Interest. When is Embecta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EMBC earnings forecast. How can I listen to Embecta's earnings call? Embecta will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) issued its quarterly earnings results on Friday, February, 9th. The company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.15. The firm had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. Embecta had a net margin of 4.93% and a negative trailing twelve-month return on equity of 18.66%. Embecta's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the business earned $0.93 earnings per share. How often does Embecta pay dividends? What is the dividend yield for Embecta? Embecta announced a quarterly dividend on Friday, February 9th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.15 per share on Friday, March 15th. This represents a $0.60 annualized dividend and a dividend yield of 5.77%. The ex-dividend date of this dividend is Tuesday, February 27th. Read our dividend analysis for EMBC. Is Embecta a good dividend stock? Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 5.51%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 27.15% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for EMBC. What ETFs hold Embecta's stock? ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Small Cap US Equity Select ETF (RNSC), Syntax Stratified SmallCap ETF (SSLY) and Invesco S&P Spin-Off ETF (CSD).Simplify Health Care ETF (PINK). What guidance has Embecta issued on next quarter's earnings? Embecta issued an update on its FY 2024 earnings guidance on Friday, February, 9th. The company provided earnings per share guidance of 1.950-2.150 for the period, compared to the consensus EPS estimate of 2.000. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Who are Embecta's major shareholders? Embecta's stock is owned by a number of institutional and retail investors. Top institutional investors include Denali Advisors LLC (0.09%), Allspring Global Investments Holdings LLC (0.04%) and Cardinal Capital Management (0.02%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EMBC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
